GLYCOIMMUNE CHECKPOINT INHIBITORS
Targeting Glycan-Sensing Checkpoints to Unleash Both the Innate and Adaptive Immune Responses to Cancer

GLYCOIMMUNE CHECKPOINT INHIBITORS
Targeting Glycan-Sensing Checkpoints to Unleash Both the Innate and Adaptive Immune Responses to Cancer

The Need

Despite the early success of first-generation immuno-oncology drugs, most cancer patients still do not achieve clinical responses.

Learn more

The Scientific Opportunity

Cell surface glycosylation is now known to play a central role in immuno-oncology: Tumor cells evolve over time, cloaking themselves in certain glycan patterns that down-regulate a wide spectrum of innate and adaptive immune cell types which are critical to fighting cancer.

Learn more

The Approach

Palleon Pharmaceuticals has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glycoimmune Checkpoint Inhibitors to treat cancer patients.

Learn more

Twitter

@Palleon_Pharma • Oct 4, 2017
At Palleon, we’re taking a pan- #immune approach against #cancer. Learn more about our science: palleonpharma.com/science-opportunity/…

@Palleon_Pharma • Oct 4, 2017
We're thrilled to officially launch Palleon Pharmaceuticals with a $47.6 million Series A funding palleonpharma.com/press-release/

Visit us on Twitter

Our Founding Science

Hear from Dr. Carolyn Bertozzi on glycoscience, glycoimmune checkpoints, and how Palleon is positioned to advance this unexplored area of immuno-oncology to benefit patients.

Learn more